BlueArc Biosciences has been a winner in all three phases so far of the LymeX Innovation Accelerator competition as it works ...

Phase 3: Implementation phase consists of taking immediate action on key priorities, such as issuing a request for proposal (RFQ)to replace the current research administration system (eRA), optimizing ...

Fears of tighter monetary policy initially sent shockwaves through risk-on assets, prompting sell-offs across various digital ...

DeepSeek’s LLM has caused a stir, but ... companies like OpenAI and Anthropic are aiming higher, their sights are set on ...

Discover seven companies operating in metabolomics, the field that could significantly boost precision medicine.

In the longer run, current price action is part of a recovery phase that could extend to ... You should do your own thorough research before making any investment decisions. FXStreet does not ...

Agentic AI systems are defined by their ability to plan and execute tasks autonomously, exhibiting properties such as ...

“OCU200 has the potential to change the treatment landscape for DME, diabetic retinopathy (DR), and wet age-related macular degeneration (wet AMD) with its unique mechanism of action, binding th ...

PFAS exposure in Europe has been linked to excess deaths and health risks, prompting biomonitoring efforts and policy action ...

Roche also included RG7827, a 4-1BBxFAP bispecific antibody, on the list of the candidates removed from its phase 1 pipeline. However, a Roche spokesperson clarified that the action relates to the ...

People want net zero, but they don’t want to do the things needed to achieve net zero, says Social Market Foundation ...

Royalty Pharma to provide R&D investment of up to $250 million for Biogen's litifilimab, a potential first-in-class biologic in Phase 3 development for the treatment of lupus. NEW ...